Informing patient management through real-world clinical data analytics

人工智能(AI)的兴起为我们提供了前所未有的机会来分析大数据集并从中获得见解。其中一个领域是医疗保健；英国国民健康保险制度通过数字医疗记录的方式，拥有国际上独一无二的患者数据数量和质量。对特定临床环境下的这些记录进行回顾分析，使我们有可能开发临床决策支持工具，显著改变未来诊断和管理患者的方式。然而，实现这一愿景存在重大挑战：数据大多存储在基于NHS的系统中，行业无法访问这些系统。企业可能拥有开发新产品的技能和资源，但与现实世界的患者护理无关。因此，有意义的创新将需要NHS、学术界和工业界之间的密切合作。这一创新学者借调将使GE Healthcare、谢菲尔德大学和谢菲尔德教学医院NHS基金会信托基金开展一项联合计划，允许GE Healthcare的Jan Wolber博士兼职到谢菲尔德大学，为期三年，战略参与几个疾病领域的联合研究和开发。这次借调的预期结果是交付几个概念验证分析应用程序，这些应用程序可以帮助心脏病学、呼吸系统医学和神经学领域的临床决策。然后，这些应用程序将由GE Healthcare正式开发成产品，部署到英国的临床实践中，从而使全国和其他地区的患者受益。这些应用程序可能会在整个NHS提供的护理服务的质量和一致性方面带来好处，并使患者能够早期诊断并分层到适当的护理路径，这反过来可以改善结果和生活质量，并可能通过在正确的时间做出正确的治疗决定来降低患者一生中的医疗成本。

The rise of artificial intelligence (AI) has given us unprecedented opportunities to analyse big data sets and to derive insights from them. One such area is healthcare; the UK NHS have internationally unique quantity and quality of patient data by way of digital medical records. The retrospective analysis of those records in specific clinical settings gives us the potential to develop clinical decision support tools that significantly change the way in which patients will be diagnosed and managed in the future.However, there are significant challenges to realising this vision: Data are mostly stored in NHS-based systems that are not accessible to industry. Businesses may have the skills and resources to develop new products but are not connected to real-world patient care. Meaningful innovation will therefore require close partnership between NHS, academia and industry. This innovation scholar secondment will enable a joint programme by GE Healthcare, the University of Sheffield and the Sheffield Teaching Hospitals NHS Foundation Trust by allowing Dr Jan Wolber from GE Healthcare to be seconded to the University of Sheffield part-time for a duration of three years to be strategically involved in joint research and development in several disease areas.The expected outcome of this secondment is the delivery of several proof-of-concept analytics applications that can assist clinical decision making in the areas of cardiology, respiratory medicine and neurology. These applications would then be formally developed into products by GE Healthcare for deployment into clinical practice in the UK, hence benefitting patients across the nation and beyond. The applications may deliver benefits in the quality and consistency of care delivery across the NHS as well as enabling early diagnosis and stratification of patients into appropriate care pathways, which in turn can improve outcomes and quality of life, as well as possibly contributing to the reduction of healthcare costs over the life of a patient by making the right treatment decisions at the right time.